Dare Bioscience to present Phase 2b results of Sildenafil Cream in FSAD

Dare Bioscience and its collaborator Strategic Science & Technologies, a Cambridge, MA based novel topical drug delivery company, announced that preliminary efficacy findings from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder – FSAD – will be presented at the upcoming Sexual Medicine Society of North America 24th Annual Meeting. Andrew Goldstein, Medical Advisor for Dare Bioscience, said, “The results I will discuss highlight important attributes and meaningful improvements across the women who benefitted from Sildenafil Cream treatment most significantly in this study, which included women with not only female sexual arousal disorder but also those who suffered from a lack of sexual desire along with decreased arousal.” “The findings from this study in arousal, desire, and orgasm among the women treated with Sildenafil Cream support the potential of Sildenafil Cream to provide improvements across the sexual experience continuum, as has been seen among men treated for erectile dysfunction with sildenafil products,” said James Simon, Clinical Professor, Obstetrics and Gynecology, George Washington University. Sildenafil is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra for the treatment of ED in men. Sildenafil Cream is an investigational, proprietary topical cream formulation designed to be used on-demand at the time of sexual activity to increase blood flow to the genital tissue in women. If development is successful, Sildenafil Cream has the potential to be the first product approved by the FDA to treat any form of arousal disorder in women.